Atara Biotherapeutics financials
$8.05−3.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — | — | — | — |
| Gross profit | $99.6M | $107.9M | $8.6M | $63.6M | — | — | — | — | — | — |
| Gross margin | 82.4% | 83.7% | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M | -$309.1M | -$295.7M | -$237.1M | -$121.5M | -$81.2M |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M | -$306.6M | -$291.0M | -$230.7M | -$119.5M | -$79.0M |
| Net margin | 27.1% | −66.2% | −3220.9% | −359.1% | — | — | — | — | — | — |
| Diluted EPS | $2.57 | $-11.41 | $-65.19 | $-56.00 | $-90.75 | $-103.75 | $-141.75 | $-131.75 | $-100.00 | $-68.75 |
| EBITDA | $38.0M | -$78.4M | -$271.2M | -$274.9M | -$331.1M | -$300.7M | -$288.6M | -$233.4M | -$120.6M | -$80.9M |
| Operating cash flow | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M | -$180.8M | -$235.6M | -$179.8M | -$87.5M | -$60.0M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M | -$231.1M | -$185.3M | -$241.4M | -$215.7M | -$107.7M | -$63.0M |
| Diluted shares | 12.7M | 7.5M | 4.2M | 4.1M | 3.7M | 3.0M | 2.1M | 1.8M | 1.2M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.5M | $25.0M | $25.8M | $92.9M | $106.1M | $200.4M |
| Short-term investments | $0.00 | $17.5M | $25.9M | $149.9M | $265.0M | $300.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M | $588.1M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M | $125.8M |
| Shareholders' equity | -$38.5M | -$97.3M | -$99.2M | $126.6M | $279.6M | $462.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology